We hypothesize that for breast cancer, on one side, treatment with anti-HER3 monoclonal antibodies would reduce the proliferation and migration of cancer cells by blocking stromal NRG1 binding, thus diminishing tumour aggressiveness. This evidence concerns the gene NRG1 and cancer.